Extrait

Strata 1 To compare the time to progression between 2 treatment arms (ZD1839/Nolvadex vs placebo/Nolvadex ) Strata 2 To compare the clinical benefit rate between 2 treatment arms (ZD1839/Nolvadex vs placebo/Nolvadex)

Critère d'inclusion

• Female patients aged ³18 years, pre/post menopausal with ER and/or PR positive metastatic adenocarcinoma of the breast determined by each laboratory in each centre. Patients will be stratified into 2 categories based on prior hormonal therapy: ·newly diagnosed metastatic disease or that completed adjuvant therapy with tamoxifen at least 1 year prior to starting this protocol ·recurrent disease during, or after adjuvant AI or failing first line treatment with AI for metastatic disease

Liens

• ictrp
• euctr